These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29270718)

  • 21. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza.
    Baranowska M; Hauge AG; Hoornaert C; Bogen B; Grødeland G
    Vaccine; 2015 Dec; 33(49):6988-96. PubMed ID: 26387432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.
    Sarawar S; Hatta Y; Watanabe S; Dias P; Neumann G; Kawaoka Y; Bilsel P
    Vaccine; 2016 Sep; 34(42):5090-5098. PubMed ID: 27595896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice.
    Joe PT; Christopoulou I; van Hoecke L; Schepens B; Ysenbaert T; Heirman C; Thielemans K; Saelens X; Aerts JL
    J Transl Med; 2019 Jul; 17(1):242. PubMed ID: 31345237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Yang WT; Yang GL; Wang Q; Huang HB; Jiang YL; Shi CW; Wang JZ; Huang KY; Jin YB; Wang CF
    Antiviral Res; 2017 Feb; 138():9-21. PubMed ID: 27908830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL
    Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.
    James CM; Abdad MY; Mansfield JP; Jacobsen HK; Vind AR; Stumbles PA; Bartlett EJ
    Vaccine; 2007 Feb; 25(10):1856-67. PubMed ID: 17240000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
    Powell TJ; Peng Y; Berthoud TK; Blais ME; Lillie PJ; Hill AV; Rowland-Jones SL; McMichael AJ; Gilbert SC; Dong T
    PLoS One; 2013; 8(5):e62778. PubMed ID: 23658773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.
    Patel A; Tran K; Gray M; Li Y; Ao Z; Yao X; Kobasa D; Kobinger GP
    Vaccine; 2009 May; 27(23):3083-9. PubMed ID: 19428922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge.
    Tian Y; Deng Z; Chuai Z; Li C; Chang L; Sun F; Cao R; Yu H; Xiao R; Lu S; Xu Y; Yang P
    Virology; 2024 Aug; 596():110125. PubMed ID: 38805804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.
    Hessel A; Savidis-Dacho H; Coulibaly S; Portsmouth D; Kreil TR; Crowe BA; Schwendinger MG; Pilz A; Barrett PN; Falkner FG; Schäfer B
    PLoS One; 2014; 9(2):e88340. PubMed ID: 24523886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
    Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
    J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    Tompkins SM; Zhao ZS; Lo CY; Misplon JA; Liu T; Ye Z; Hogan RJ; Wu Z; Benton KA; Tumpey TM; Epstein SL
    Emerg Infect Dis; 2007 Mar; 13(3):426-35. PubMed ID: 17552096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.